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Summary The anticancer drug paclitaxel is formulated for
i.v. administration in a mixture of Cremophor EL and ethanol.
Its oral bioavailability is very low due to the action of P-
glycoproteininthe gut wallandCYP450ingutwallandliver.
However, proof-of-concept studies using the i.v. formulation
diluted in drinking water have demonstrated the feasibility of
the oral route as an alternative when given in combination
withinhibitorsofP-glycoproteinandCYP450.Becauseofthe
unacceptable pharmaceutical properties of the drinking
solution, a better formulation for oral application is needed.
We have evaluated the suitability of various self-micro
emulsifying oily formulations (SMEOF’s) of paclitaxel for




that this vehicle does not enhance intestinal uptake by itself.
Paclitaxel (10 mg/kg) in SMEOF#3 given with CsA resulted
in plasma levels that were comparable to the Cremophor EL-
ethanol containing drinking solution plus CsA. Whereas the
AUC increased linearly with the oral paclitaxel dose in
P-glycoprotein knockout mice, it increased less than propor-
tional in wild-type mice given with CsA. In both strains more
unchanged paclitaxel was recovered in the feces at higher
doses. This observation most likely reflects more profound
precipitation of paclitaxel within the gastro-intestinal tract at
higherdoses.Theresultingabsolutereductioninabsorptionof
paclitaxel from the gut was possibly concealed by partial
saturation of first-pass metabolism when P-glycoprotein was
absent. In conclusion, SMEOF’sm a y b eau s e f u lv e h i c l ef o r
oral delivery of paclitaxel in combination with CsA, although
the physical stability within the gastro-intestinal tract remains
a critical issue, especially when applied at higher dose levels.
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Paclitaxel is a widely used anticancer agent that is
administered by an intravenous (i.v.) infusion [1, 2].
Because the drug is poorly soluble in most pharmaceutical
solvents it is formulated at a concentration of 6 mg/ml in a
1:1 mixture of Cremophor® EL (CrEL) and ethanol.
Consequently, substantial amounts of these excipients are
co-infused at the standard dose level of 175 mg/m
2.
However, CrEL has been associated with sometimes severe
hypersensitivity reactions [3] and non-linear pharmacokinetic
behaviour of i.v. administered paclitaxel [4–6].
In general, the oral route for the administration of drugs
is considered to be more attractive than the i.v. route
because of its greater convenience for patients and because
of pharmacoeconomic advantages [7, 8]. In addition, the
oral route facilitates repeated dosings, thereby prolonging
the exposure time, which may be advantageous in case of
cell cycle specific agents, such as paclitaxel. Unfortunately,
however, oral dosing of paclitaxel is not a feasible option as
paclitaxel has a very low oral bioavailability. This is mainly
due to the action of the drug efflux transporter P-
glycoprotein (P-gp) that is highly expressed in gastrointes-
tinal tract and limits the uptake of drug from the intestinal
lumen. Studies in mice have shown that whereas 87% of an
orally administered dose of paclitaxel was recovered as
unchanged drug in the feces of wild-type mice, excretion
was reduced to 2% in P-gp knockout mice [9] indicating
complete uptake from the gastro-intestinal tract when P-gp
is absent. However, paclitaxel that does enter into the body
is subjected to extensive first-pass metabolism by the gut
and liver cytochrome P450 (CYP) enzymes (CYP2C8 and
CYP3A4) [10], rendering the oral bioavailability in P-gp
knockout mice about 40% [9]. In line with these results,
concomitant administration of agents that block the function
of P-gp and/or CYP, e.g. cyclosporin A (CsA), have
successfully been used to increase the systemic exposure to
the i.v. paclitaxel formulation after oral administration in mice
and patients [11–13].
The design of an oral formulation of paclitaxel for use in
patients remains a critical issue. So far, studies in patients
have been conducted with the marketed formulation for i.v.
administration, which is diluted with water before admin-
istration to yield an oral drinking solution [12, 14, 15].
Although these studies have shown that oral administration
of paclitaxel is feasible and associated with antitumor
efficacy [14–16], there are issues with the oral drinking
solution that preclude its more widespread implementation
in clinical practice. One of these concerns is the presence of
substantial amounts of CrEL, which, when given at higher
doses, antagonizes the absorption of paclitaxel from the GI
tract [17–19] and for that reason, higher dose intensities can
only be delivered by repeated administration. However,
CrEL gives the drinking solution an appalling taste
resulting in intolerance, nausea and vomiting, especially
when administered repeatedly. A possible solution to this
issue may be to prepare a Self-Microemulsifying Oily
Formulations (SMEOF) in which paclitaxel is encapsulated
into 1–10 nm size oily droplets. The formulations consist of
isotropic mixtures of oils and surfactants, which solubilize
paclitaxel and spontaneously form a microemulsion upon
contact with water. In a previous in vitro study the choice of
the excipients was motivated by the particle size, physical and
chemical stability as well as cytotoxicity of different self-
emulsingdrugdeliverysystemformulationsofpaclitaxel[20].
In the different SMEOF formulations tyloxapol and TPGS
(d-alpha-tocopherylpolyethyleneglycol1000succinate)have
been chosen for their ability to solubilize paclitaxel [20–23].
As compared to the commercial paclitaxel (Taxol®) formu-
lation tested orally, the SMEOF formulations are CrEL-free
and have a significantly lower ethanol to paclitaxel ratio.
The purpose of this preclinical study was to test the
suitability of SMEOFs to serve as an oral delivery
formulation of paclitaxel. We selected the most appropriate
candidate for further investigations. In particular, we
addressed the issue of the linearity of the relationship




SMEOF#1 (1.5%), SMEOF#2 (3.0%), SMEOF#3 (1.5 or
3.0%), SMEOF#4 (1.5%) (contents of paclitaxel between
parenthesis; see Table 1 for compositions) were prepared by
Novagali Pharma SA, (Evry Cedex, France). SMEOF#4 is
identical to SMEOF#3, except that this formulation already
contains cyclosporine A at a concentration of 1.5%.
Cyclosporin A (Sandimmune) originated from Novartis
(Basel, Switzerland), Taxol® from Bristol-Meyers Squibb
(München, Germany) and pure paclitaxel was obtained
from Novagali. Polysorbate 80 was purchased from
Brocacef B.V. (Maarssen, The Netherlands). All other
chemicals were of analytical or lichrosolv gradient grade
and originated from E. Merck (Darmstadt, Germany).
Drug-free human plasma used for preparation of calibration
curves [24] was obtained from the Central Laboratory of
the Blood Transfusion Service (Sanquin, Amsterdam, The
Netherlands).
Animals
Mice were housed and handled according to institutional
guidelines complying with Dutch legislation. Animals
Invest New Drugs (2011) 29:768–776 769used in all experiments were female Mdr1a/1b
−/− (P-gp
knockout) and wild-type (WT) mice of FVB genetic
background between 10 and 16 weeks of age. Animals
were kept in a temperature-controlled environment with a
12-hour light/12-hour dark cycle. They received a standard
diet (AM-II, Hope Farms, Woerden, The Netherlands) and
acidified water ad libitum.
Drug solutions
SMEOF#1, SMEOF#2 are two-phase formulations that
were quantitatively mixed just prior to 10-fold dilution
in sterile water while SMEOF#4 working solution was
also prepared by 10-fold dilution in water. Final
paclitaxel concentrations were 1.5, 3.0, and 1.5 mg/
mL for SMEOF# 1, 2 and 4, respectively. SMEOF#3
(1.5%) was diluted 5 and 10-fold, while SMEOF#3
(3.0%) was diluted 10 and 20-fold with water for
injection to yield final concentrations of 3.0 and
1.5 mg/mL of paclitaxel, respectively. Cyclosporin A
(CsA) 50 mg/mL was diluted 25-fold with water for
injection. Taxol® (paclitaxel; 6 mg/ml in CrEL:Ethanol
1:1; v/v) was diluted 4-fold with water for injection.
Paclitaxel (6 mg/ml) in polysorbate/ethanol (1:1; v/v)w a s
prepared at our institute and was diluted 4-fold with
saline for injection.
Plasma pharmacokinetics and oral bioavailability
In the first part of the study, cohorts of WT mice were
treated orally with one of the four different SMEOF
working solutions and Taxol® as a reference at a dose
level of 10 mg/kg of paclitaxel. Separate cohorts of
mice received paclitaxel (formulated in Polysorbate 80:
ethanol) i.v. in order to calculate the absolute bioavail-
ability. Polysorbate 80-ethanol and not the standard i.v.
Formulation Component Percentage % (w/v) Function
SMEOF#1 (1.5%) Phase A Phase B
Paclitaxel – 1.5 Active substance
Vitamin E 5.00 – Oil
TPGS 14.24 14.25 Surfactant, co-solvent
Tyloxapol 15.75 15.75 Surfactant, co-solvent
Ethanol 15.25 15.25 Solvent
Doc-Na 3.00 – Surfactant
Total 53.24 46.75
SMEOF#2 (3.0%) Phase A Phase B
Paclitaxel – 3.0 Active substance
Vitamin E 5.00 – Oil
TPGS 14.00 14.00 Surfactant, co-solvent
Tyloxapol 15.50 15.50 Surfactant, co-solvent
Ethanol 15.00 15.00 Solvent
Doc-Na 3.00 – Surfactant
Total 52.50 47.50
SMEOF#3 (1.5% and 3.0%) (1.5%) (3.0%)
Paclitaxel 1.5 3.0 Active substance
Vitamin E 5.00 5.00 Oil
TPGS 29.95 29.45 Surfactant, co-solvent
Tyloxapol 33.05 32.55 Surfactant, co-solvent
Ethanol 30.5 30.0 Solvent
Total 100 100
SMEOF#4 (1.5%) Paclitaxel 1.5 Active substance
Cyclosporin A 1.5 P-gp inhibitor
Vitamin E 5 Oil
TPGS 29.45 Surfactant, co-solvent
Tyloxapol 32.55 Surfactant, co-solvent
Ethanol 30 Solvent
Total 100







770 Invest New Drugs (2011) 29:768–776formulation of CrEL-ethanol was used to avoid the
CrEL mediated nonlinear plasma pharmacokinetics of
paclitaxel [4, 5]. Oral drug administrations were given by
gavage into the stomach. The SMEOF solutions were
aliquoted in small portions in order to have fresh and
clear drug solutions for all animals. By working this way
we avoided precipitation from the formulation that
sometimes occurred within minutes after the gavage.
The animals were treated with or without concomitant
administration of CsA (10 mg/kg), given at 20 min prior
to oral paclitaxel or 30 min prior to i.v. paclitaxel. No
concomitant CsA was given to animals receiving
SMEOF#4 as this formulation already contains CsA. In
the second part, WT and P-gp knockout mice received
paclitaxel in SMEOF#3 at dose levels of 10, 30 and
60 mg/kg. The WT mice also received oral CsA (10 mg/
kg), 20 min prior to oral paclitaxel. An additional cohort
of P-gp knockout mice received i.v. paclitaxel formulated
in Polysorbate 80: ethanol (1:1; v/v). In the third part, the
properties of SMEOF#3 (containing 30 mg/ml (3%, w/w)
of paclitaxel) was investigated in P-gp knockout mice.
These animals received dose levels of 10, 30 and 60 mg/
kg. In all these pharmacokinetic experiments, five
animals per time point were euthanized for blood
s a m p l i n gb yc a r d i a cp u n c t u r ea t1 ,2 ,4 ,a n d8ha f t e r
administration. The plasma fraction of the blood samples
was collected after centrifugation at 5,000× g for 10 min
a t4 ° C ,a n ds t o r e da t−20°C until analysis.
Fecal excretion
WT and P-gp knockout mice were individually housed
in Ruco Type M/1 metabolic cages (Valkenswaard, The
Netherlands). They were first accustomed to the cages
for 2 days before receiving paclitaxel in SMEOF#3
(1.5%) working solution at dose levels of 10, 30 and
60 mg/kg (five animals per dose). The WT mice also
received CsA (10 mg/kg), 20 min prior to oral
paclitaxel. Additionally, P-gp knockout mice received
paclitaxel orally in SMEOF#3 (3.0%) paclitaxel at dose
levels of 10, 30 and 60 mg/kg (five animals per dose).
The feces were collected every 24 h for up to 96 h.
Feces were pooled per animal and homogenized in 4%
(w/v) BSA in water. The samples were stored at −20°C
until analysis.
Drug analysis
Amounts of paclitaxel in all biological samples were
determined using a previously described validated high-
performance liquid chromatography assay [24, 25] with a
lower limit of quantification of 25 ng/ml using 250 µlo f
sample.
Pharmacokinetic and statistical analysis
Pharmacokinetic parameters were calculated by non-
compartmental methods using the software package Quattro
Pro (Corel Corp., 1996; version 6.02). The area under the
plasma concentration-time curve (AUC) was calculated
from time = 0 to the time of the last sampling point with a
concentration above the LLQ (Clast) using the linear
trapezoidal rule without extrapolation to infinity using the
formula
with Δtimen=0
The standard error (SE) of the AUC was calculated with
the law of propagation of errors using the formula:
The maximal plasma concentration (Cmax) and the time
at which the maximal plasma level was reached (Tmax) were
determined graphically. The oral bioavailability (F) was
calculated using the formulas:
F ¼ AUCoral=AUCi:v: ðÞ »100%
The SE(F) was calculated using:
SE F ðÞ¼ F   SE AUC;oral ðÞ =AUCoral
   2
þ SE AUCi:v: ðÞ =AUCi:v:
   2
The unpaired Student’s t-test (two-tailed) was used to
compare the pharmacokinetic parameters. P-values < 0.05
were considered statistically significant.
Results
Plasma pharmacokinetics of oral paclitaxel formulated
in different SMEOFs in Wild-type and P-gp knockout mice
We first compared the oral bioavailability of paclitaxel in the
four different SMEOF working solutions using the standard
Taxol® solution as reference. To determine the systemic
exposure after i.v. injection we used paclitaxel formulated in
polysorbate 80-ethanol instead of the standard CrEL-ethanol
formulation in order to avoid the nonlinear pharmacokinetic
behavior of paclitaxel in this vehicle [4, 5]. As expected, the
paclitaxel plasma levels were low with all tested oral
SMEOF working solutions when administered without CsA
(Table 2 and Fig. 1). In combination with CsA, SMEOF#1
and SMEOF#2 resulted in a lower paclitaxel exposure when
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4
 ! v u u tcompared with the standard Taxol® formulation. Moreover,
some turbidity of the diluted SMEOF#1 and #2 paclitaxel
formulations started to occur within minutes after the first
administration. For these reasons, and because these two-
Phase systems were less convenient, the development of
SMEOF#1 and #2 was discontinued. The administration of
paclitaxel formulated in SMEOF#3 in combination with
CsA and of SMEOF#4 (which contains CsA) resulted in
systemic exposures that were similar to those obtained
with the standard Taxol® formulation (Table 2 and Fig. 1).
The oral bioavailability ranged from 18.4 to 21.7%.
Turbidity was not observed in these samples. In conclu-
sion, the results of this study showed that the formulations
SMEOF#3 and SMEOF#4 in combination with CsA are
promising alternatives to the standard Taxol® formulation.
In the next mouse experiments we have chosen to further
explore the SMEOF#3 paclitaxel formulation in combina-
tion with CsA.
Systemic exposure of paclitaxel formulated in SMEOF#3
in wild-type and P-gp knockout mice
When P-gp knockout mice received SMEOF#3 (1.5%)
orally at doses of 10, 30, or 60 mg/kg of paclitaxel, the
exposure (AUC) increased in a dose-proportional manner
(Table 3 and Fig. 2). The mean oral bioavailability of
paclitaxel ranged from 29.9 to 38.6%. Figure 3 reveals
that the Tmax is longer at higher dose levels. When WT
mice received SMEOF#3 at 10, 30, or 60 mg/kg of
paclitaxel in combination with CsA (10 mg/kg), the
increase in the exposure to paclitaxel was not proportional
with dose. Consequently, the absolute bioavailability
decreased at higher dose levels (Table 3;F i g .2). Overall,
the exposure to paclitaxel in WT mice treated at a dose of
10 mg/kg of paclitaxel in combination with CsA was
similar as in P-gp knockout mice treated with 10 mg/kg of
paclitaxel in SMEOF#3. Since the concomitant oral
administration of CsA (10 mg/kg) also increased the
exposure of i.v. administered paclitaxel, the oral bioavail-
ability in WT mice was lower (Table 2). Similar as
Fig. 1 Paclitaxel plasma concentration versus time curves after oral
administration of different SMEOF (SMEOF#1–SMEOF#4, 1.5%
w/w paclitaxel) formulations and Taxol® or i.v. administration of
paclitaxel in a Polysorbate 80: ethanol solution in wild-type with or
without co-administration of Cyclosporin A (10 mg/kg). Plasma levels
of paclitaxel were determined by a validated HPLC method with
lower limit of quantification (25 ng/mL). Data points are expressed as
mean concentrations for oral and i.v. (n=5) administration; error bars
indicate Standard Errors (SEs)
Table 2 Plasma pharmacokinetic parameters of paclitaxel (10 mg/kg) after oral treatment of the different SMEOF formulations (SMEOF#1 -
SMEOF#4, 1.5% w/w paclitaxel) and Taxol® or after i.v. administration of paclitaxel in a Polysorbate80: ethanol solution in wild-type mice with
or without co-administration of Cyclosporin A (10 mg/kg). Data are mean ± Standard error (SE), oral and i.v. administration (n=5)







SMEOF#1 10 mg/kg, p.o. – 306±46 5.2±0.8
SMEOF#1 10 mg/kg, p.o. 10 mg/kg, p.o. 1652±181 12.0±1.4
SMEOF#2 10 mg/kg, p.o. – 173±40 2.9±0.7
SMEOF#2 10 mg/kg, p.o. 10 mg/kg, p.o. 1480±160 10.8±1.3
SMEOF#3 10 mg/kg, p.o. – 108±17 1.8±0.3
SMEOF#3 10 mg/kg, p.o. 10 mg/kg, p.o. 2534±177 18.4±1.6
SMEOF#4 10 mg/kg, p.o. 10 mg/kg, p.o. 2769±307 20.1±2.7
Taxol® 10 mg/kg, p.o. – 417±64 7.1±1.2
10 mg/kg, p.o. 10 mg/kg, p.o. 2984±173 21.7±1.6
Polysorbate 80 EtOH 10 mg/kg, i.v. – 5862±366 n/a
10 mg/kg, i.v. 10 mg/kg, p.o. 13754±670 n/a
AUC0 1 Area under the concentration time curve from 0 to the last time point with a concentration above the LLQ (Tlast), F oral bioavailability,
n/a not applicable
Table 2 Plasma pharmacokinetic parameters of paclitaxel (10 mg/kg)
after oral treatment of the different SMEOF formulations (SMEOF#1 -
SMEOF#4, 1.5% w/w paclitaxel) and Taxol® or after i.v. administration
of paclitaxel in a Polysorbate80: ethanol solution in wild-type mice with
or without co-administration of Cyclosporin A (10 mg/kg). Data are
mean ± Standard error (SE), oral and i.v. administration (n=5)
772 Invest New Drugs (2011) 29:768–776observed in P-gp knockout mice the Tmax was delayed at
the higher dose levels.
When P-gp knockout mice received the SMEOF#3 with
a higher load of paclitaxel SMEOF#3 (3%) the oral
bioavailability at 10 mg/kg was similar to that observed
using SMEOF#3 (1.5%) (Table 3; Fig. 2). However, the
oral bioavailability decreased markedly when higher dose
levels were administered. Moreover, turbidity was also
observed in the diluted formulations within 5 to 15 min
after the first administration.
Fig. 2 Paclitaxel plasma concentration versus time curves after oral
administration of the SMEOF#3 formulation with 1.5% w/w and 3.0%
w/w paclitaxel at different doses of 10, 30, or 60 mg/kg in P-gp
knockout (a and b) and wild-type mice (c) co-administered with
Cyclosporin A (10 mg/kg). Plasma levels of paclitaxel were
determined by a validated HPLC method with lower limit of
quantification (25 ng/mL). Data points are expressed as mean
concentrations for oral (n=5) administration; error bars indicate
Standard Errors (SEs)
Paclitaxel formulation Paclitaxel Cyclosporin A AUC0-Tlast (ng/mL*h) F (%)
P-gp knockout mice
SMEOF#3, (1.5%) 10 mg/kg, p.o. – 1841±166 29.9±3.1
SMEOF#3, (1.5%) 30 mg/kg, p.o. – 7110±382 38.6±2.8
SMEOF#3, (1.5%) 60 mg/kg, p.o. – 11220±1131 30.4±3.4
Polysorbate 80:EtOH 10 mg/kg, i.v. – 6147±291 n/a
Wild-type mice
SMEOF#3, (1.5%) 10 mg/kg, p.o. 10 mg/kg, p.o. 2090±174 15.2±1.5
SMEOF#3, (1.5%) 30 mg/kg, p.o. 10 mg/kg, p.o. 3835±430 9.3±1.1
SMEOF#3, (1.5%) 60 mg/kg, p.o. 10 mg/kg, p.o. 5916±765 7.2±1.0
Polysorbate 80 EtOH 10 mg/kg, i.v. 10 mg/kg, p.o. 13754±670 n/a
P-gp knockout mice
SMEOF#3, (3.0%) 10 mg/kg, p.o. 1710±131 27.8±2.5
SMEOF#3, (3.0%) 30 mg/kg, p.o. 3871±621 21.0±3.5
SMEOF#3, (3.0%) 60 mg/kg, p.o. 1764±168 4.8±0.5
Table 3 Plasma pharmacokinetic
parameters of paclitaxel after oral
treatment of the SMEOF#3
formulation (with 1.5% w/w and
3.0% w/w paclitaxel) at different
doses of 10, 30, or 60 mg/kg or
after i.v. administration of pacli-
taxel in a Polysorbate80: ethanol
solution in P-gp knockout and/or
wild-type mice co-administered
with or without Cyclosporin A
(10 mg/kg). Data are mean ±
Standard error (SE), oral and i.v.
administration (n=5)
AUC0-Tlast Area under the
concentration time curve from 0
to the last time point with a
concentration above the LLQ
(Tlast), F oral bioavailability, n/a
not applicable
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in Wild-type and P-gp knockout mice
When SMEOF#3 (1.5%) was administered orally at doses
of 10, 30, or 60 mg/kg of paclitaxel to P-gp knockout mice,
the recovery of unchanged paclitaxel in the feces increased
with dose from 27.9%±2.4% to 56.4±5.3% of the
administered dose, whereas the recovery ranged up to
84.7%±5.2% when using SMEOF#3 (3%)(Fig. 3). Thus,
the fecal recovery of paclitaxel in P-gp knockout mice was
considerably higher with SMEOF#3 (3.0%) than with
SMEOF#3 (1.5%), which is in line with the finding that
the plasma concentration and oral bioavailability of
paclitaxel in SMEOF#3 (3%) was lower. The fecal
excretion of paclitaxel in WT mice receiving SMEOF#3
(1.5%) in combination with CsA, increased with dose from
60.1 to 95.0% (Fig. 3), indicating that intestinal P-gp was
not completely inhibited by CsA.
Discussion
The present study shows that SMEOFs are potentially
suitable as delivery vehicles for oral administration of
paclitaxel when administered in combination with a P-gp
inhibitor such as CsA. We selected SMEOF#3 for more
extensive studies because the systemic exposure and
bioavailability of paclitaxel after oral administration of
SMEOF#3 was comparable to the standard drinking
solution containing Cremophor EL:ethanol (Taxol®). The
oral bioavailability of paclitaxel in mice receiving the
drinking solution is about 40% [9], which is a good starting
point. For patients, however, the drinking solution suffers
from an unacceptable bitter taste and also leads to a high
concomitant ethanol consumption. Moreover, in patients
the bioavailability is reduced when higher dose levels are
given [19]. SMEOF#1 and #2 are less practical since they
are two-phase solutions that require mixing prior to
administration. Moreover, it appeared that they were less
stable, which resulted in lower exposures when compared
to SMEOF#3. SMEOF#4 is identical to SMEOF#3, except
that it already contains CsA and was at least as good as
SMEOF#3. Although such a combination of paclitaxel and
a P-gp/CYP450 inhibitor in one formulation holds attrac-
tive perspectives for future clinical implementation, it was
considered more appropriate to use the single drug
formulation in this preclinical-mechanistic investigation.
There are two major issues that need to be addressed in
order to achieve adequate exposure of paclitaxel after oral
administration. The first issue is that it is essential to block
and/or bypass the action of P-gp in the intestinal wall as this
drug transporter is mainly responsible for the negligible
uptake of paclitaxel by the enterocytes [9]. Changing the
formulation from a system of co-solvents to a SMEOF was
not sufficient to bypass P-gp as the exposure of paclitaxel
in WT mice receiving paclitaxel in various SMEOF’s
without concomitant CsA was very low. Consequently, a
combination of paclitaxel in SMEOFs with a P-gp inhibitor
is mandatory to yield acceptable oral bioavailabilities.
The second issue concerns the composition and stability
of the formulation in the gastro-intestinal tract, as this
determines the rate at which paclitaxel will be released from
the carrier and becomes available for uptake through the
intestinal wall. If degradation of the carrier occurs too slowly,
as with CrEL, a substantial fraction of the dose will leave the
body without having had the opportunity for uptake by
enterocytes [17]. On the other hand, if the release from the
carrier occurs too rapidly, there is a chance of irreversible
precipitation of the liberated and water-insoluble paclitaxel
molecules within the intestinal lumen. By using P-gp
knockout mice we were able to study this latter issue
without having to take into account the action of P-gp.
The plasma pharmacokinetics and fecal excretion of
paclitaxel were evaluated at three different dose levels in
P-gp knockout mice. At the lowest dose level of 10 mg/kg
the plasma AUC is very similar to the AUC achieved in
patients receiving oral paclitaxel in the CrEL containing
drinking solution together with oral CsA (1.5–3.5 µM￿h ≈
1,200–2,400 ng/ml￿h) [19], although the direct comparison
is somewhat tricky because the shape of the curves in mice
and humans differ with higher Cmax, shorter Tmax and
shorter elimination half-life in mice. When patients receive
increasing doses of oral paclitaxel, the plasma AUC
increases only marginally because of entrapment of
paclitaxel in CrEL micelles in the intestinal lumen [17,
18]. Although the finding that the plasma AUC of
paclitaxel in mice increased proportional with dose when
using SMEOF#3 suggested that the uptake by the intestines
Fig. 3 Fecal excretion of paclitaxel in P-gp knockout and Wild-type
mice co-administered with CsA (10 mg/kg). The mice were housed in
metabolic cages and were treated with an oral administration of
SMEOF#3 (with 1.5% w/w or 3.0% w/w paclitaxel) at different doses
of 10, 30, or 60 mg/kg. Paclitaxel levels were measured in feces
excreted between 0–96 h using a validated HPLC method. Results are
expressed as percentage of the given dose; Bars ± SE (n=5)
774 Invest New Drugs (2011) 29:768–776was also independent of the dose, this was not the case. The
fecal excretion of unchanged drug at the 10 mg/kg dose
was already much higher than the less than 2% previously
observed with the CrEL drinking solution [9] and the fecal
excretion further increased with dose. Because the fecal
excretion of unchanged drug was even more pronounced
when the amount of carrier relative to paclitaxel was
reduced as in SMEOF#3 (3%), it is most likely that a rapid
degradation of the carrier is responsible for the reduced
intestinal uptake. Apparently, this formulation may not be
stable enough to contain paclitaxel at this concentration in
order to protect paclitaxel from precipitation in the gastro-
intestinal tract. Moreover, gastric emptying in mice was
delayed at the higher dose levels, as indicated by the longer
Tmax, leaving even more time for degradation of the carrier
before the drug enters into the intestines. In view of this, the
finding that the plasma level of paclitaxel increased dose-
proportionally, in spite of the fact that the uptake at higher
dose levels occurs less efficiently, is most likely caused by
saturation of first-pass metabolism at the higher doses. In a
previous pilot study with SMEOF#3 (1.6%) in patients, it
was observed that the AUC was similar, but that the Tmax
was shorter and the Cmax was higher than with the CrEL
drinking solution [26]. This finding is consistent with the
idea that paclitaxel becomes more readily available for
uptake when given in SMEOF#3. Astheloadofpaclitaxelin
SMEOF#3 appears to be an important determinant for the rate
of release, future clinical studies aimed at establishing the
dose-AUC proportionality of oral paclitaxel with SMEOF#3
should include the testing of different loads.
Asexpected,thefecalrecoverywashigherinWTmicedue
to reduced intestinal uptake because of incomplete inhibition
of P-gp by CsA. We have used a dose level of 10 mg/kg of
CsA because we previously found that increasing the dose to
50 mg/kg did not further increase the oral bioavailability [12].
Moreover, this lower dose was preferred because we wanted
to avoid as much as possible an interaction between the
SMEOF and CrEL that is present in the CsA formulation.
For this reason there was also a 20 min lag time between the
two subsequent oral administrations. Incomplete inhibition
of P-gp was more pronounced at higher dose levels of
SMEOF#3. Whereas it is possible that the dose level of
CsA was too low to compete for the higher quantities
of paclitaxel, it is also likely that it is a consequence of
the delayed gastric emptying. Due to this effect, CsA that
was given 20 min prior to paclitaxel had already moved
to lower parts of the intestinal tract when a substantial
fraction of the dose of paclitaxel was still present in the
stomach. Both the dose and the timing issues would be
addressed when the formulation would hold both
paclitaxel and the inhibitor as in SMEOF#4 and this is
certainly an option to test in future clinical studies.
In conclusion, our preclinical mechanistic studies with oral
administration of paclitaxel in novel SMEOFs showed that
SMEOF#3 is a potentially suitable vehicle for oral delivery of
paclitaxel when given in combination with a P-gp inhibitor
such as CsA. Our results revealed that the bioavailability and
the systemic exposure to paclitaxel after a single oral
administration of SMEOF#3 were comparable to the standard
Cremophor EL: ethanol formulations. The load of paclitaxel
in the formulation appears to be important with respect to the
stability of paclitaxel in the gastro-intestinal tract and can be
used to optimize the bioavailability and dose-proportionality
of systemic drug exposure after oral administration in future
clinical studies.
Open Access This article is distributed under the terms of the
Creative Commons Attribution Noncommercial License which per-
mits any noncommercial use, distribution, and reproduction in any
medium, provided the original author(s) and source are credited.
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